Table 8.

Relative risk of events according to ASA (n = 9078) and placebo treatment (n = 9049); comparison of patients with serum creatinine concentration >1.5 mg/dl and ≤1.5 mg/dl at baselinea

Serum Creatinine >1.5 mg/dl Serum Creatinine ≤1.5 mg/dl
Events Relative Risk 95% CI P Value (ASA/pl) Relative Risk 95% CI P Value (ASA/pl) P Value (ASA/pl in Low Versus High Serum Creatinine)
aASA, acetylsalicylic acid; pl, placebo.
bNonfatal myocardial infarction, nonfatal stroke, and all cardiovascular deaths.
Major cardiovascular eventsb
ASA
placebo 0.55 0.30-1.01 0.06 0.87 0.75-1.02 0.09 0.16
All MI
ASA
placebo 0.15 0.02-1.19 0.07 0.66 0.50-0.88 0.005 0.16
All stroke
ASA
placebo 0.34 0.11-1.05 0.06 1.05 0.83-1.33 0.71 0.06
Cardiovascular mortality
ASA
placebo 0.66 0.31-1.42 0.29 0.99 0.77-1.27 0.91 0.33
Total mortality
ASA
placebo 0.63 0.35-1.11 0.11 0.96 0.81-1.14 0.68 0.16